Cargando…

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer

Androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Commonly, this is achieved with medical androgen deprivation rather than surgical intervention as the permanence and psychological effects of the latter are unacceptable for most patients. Degarelix...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rick, Ferenc G, Block, Norman L, Schally, Andrew V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633549/ https://www.ncbi.nlm.nih.gov/pubmed/23620672 http://dx.doi.org/10.2147/OTT.S32426

Ejemplares similares

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones
por: Schally, Andrew V, et al.
Publicado: (2015)

Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands
por: Roshani, Hossain, et al.
Publicado: (2021)

Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels
por: Popovics, Petra, et al.
Publicado: (2014)

Evaluation of degarelix in the management of prostate cancer
por: Van Poppel, Hendrik
Publicado: (2010)

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers
por: Perez, Roberto, et al.
Publicado: (2012)

Degarelix and its therapeutic potential in the treatment of prostate cancer
por: Doehn, Christian, et al.
Publicado: (2009)

Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer
por: Sankaran, Sindhu, et al.
Publicado: (2023)

Grade-dependent Response to Finasteride in Early Prostate Cancer
por: Rick, Ferenc G., et al.
Publicado: (2016)

Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone
por: Jaszberenyi, Miklos, et al.
Publicado: (2013)

Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer
por: Tokiwa, Suguru, et al.
Publicado: (2017)

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design
por: Melloni, Chiara, et al.
Publicado: (2020)

Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
por: Wallach, Joshua D., et al.
Publicado: (2021)

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer
por: Sciarra, Alessandro, et al.
Publicado: (2016)

Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis
por: Hosseini, Seyed Alireza, et al.
Publicado: (2016)

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis
por: Yan, Jianzhou, et al.
Publicado: (2022)

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer: Erratum
Publicado: (2016)

Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer
por: Lazenby, Mark
Publicado: (2012)

Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix
por: Ong, Shawn Y., et al.
Publicado: (2015)

Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study
por: Perez, Roberto, et al.
Publicado: (2014)

Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy
por: Madhu, Basetti, et al.
Publicado: (2016)

Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
por: Sun, Yinghao, et al.
Publicado: (2020)

Effects of Docetaxel plus Degarelix on Quality of Life and Vascular Endothelial Growth Factor in Patients with Prostate Cancer
por: Li, Weiping, et al.
Publicado: (2022)

New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor
por: Kanashiro-Takeuchi, Rosemeire M., et al.
Publicado: (2015)

Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease
por: Jaszberenyi, Miklos, et al.
Publicado: (2012)

Powerful Inhibition of Experimental Human Pancreatic Cancers by Receptor Targeted Cytotoxic LH-RH analog AEZS-108
por: Szepeshazi, Karoly, et al.
Publicado: (2013)

Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction
por: Czikora, Istvan, et al.
Publicado: (2014)

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
por: Ozono, Seiichiro, et al.
Publicado: (2018)

Investigation of the GnRH antagonist degarelix isomerization in biological matrices
por: Ferrazzano, Lucia, et al.
Publicado: (2023)

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108)
por: Szepeshazi, Karoly, et al.
Publicado: (2012)

Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study
por: Palumbo, Carlotta, et al.
Publicado: (2021)

In Search of the Molecular Mechanisms Mediating the Inhibitory Effect of the GnRH Antagonist Degarelix on Human Prostate Cell Growth
por: Sakai, Monica, et al.
Publicado: (2015)

Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men
por: Olsson, Håkan, et al.
Publicado: (2017)

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
por: Jungwirth, A., et al.
Publicado: (1997)

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
por: Autio, Karen A., et al.
Publicado: (2021)

Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study
por: You, Dalsan, et al.
Publicado: (2015)

Mistaken administration of a repeat loading dose of Degarelix leading to acute psychosis
por: Hamdoon, Musaab, et al.
Publicado: (2021)

The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK
por: Rosario, Derek J., et al.
Publicado: (2016)

Tumorigenic transformation of human prostatic epithelial cell line RWPE‐1 by growth hormone‐releasing hormone (GHRH)
por: Muñoz‐Moreno, Laura, et al.
Publicado: (2022)

Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
por: Ulm, Michael, et al.
Publicado: (2019)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_isn4113gkcd65b191cc4936hir